Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer

Autor: Groen, J.V., Michiels, N., Roessel, S. van, Besselink, M.G., Bosscha, K., Busch, O.R., Dam, R. van, Eijck, C.H.J. van, Koerkamp, B.G., Harst, E. van der, Hingh, I.H. de, Karsten, T.M., Lips, D.J., Meijer, V.E. de, Molenaar, I.Q., Nieuwenhuijs, V.B., Roos, D., Santvoort, H.C. van, Wijsman, J.H., Wit, F., Zonderhuis, B.M., Vos-Geelen, J. de, Wasser, M.N., Bonsing, B.A., Stommel, M.W.J., Mieog, J.S.D., Dutch Pancreatic Canc Grp

Publikováno v: British Journal of Surgery, 109(1), 96-104. OXFORD UNIV PRESS
British Journal of Surgery, 109(1), 96-104. Wiley
British Journal of Surgery, 109, 1, pp. 96-104
The British journal of surgery, 109(1), 96-104. John Wiley & Sons Ltd.
Groen, J V, Michiels, N, van Roessel, S, Besselink, M G, Bosscha, K, Busch, O R, van Dam, R, van Eijck, C H J, Koerkamp, B G, van der Harst, E, de Hingh, I H, Karsten, T M, Lips, D J, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, Roos, D, van Santvoort, H C, Wijsman, J H, Wit, F, Zonderhuis, B M, de Vos-Geelen, J, Wasser, M N, Bonsing, B A, Stommel, M W J & Mieog, J S D 2022, ' Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer : Impact on short-And long-Term outcomes in a nationwide cohort analysis ', British Journal of Surgery, vol. 109, no. 1, pp. 96-104 . https://doi.org/10.1093/bjs/znab345
British Journal of Surgery, 109(1), 96-104. John Wiley and Sons Ltd
The British journal of surgery, 109(1), 96-104. John Wiley and Sons Ltd
British Journal of Surgery, 109, 96-104

Background Venous resection of the superior mesenteric or portal vein is increasingly performed in pancreatic cancer surgery, whereas results of studies on short- and long-term outcomes are contradictory. The aim of this study was to evaluate the imp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3bff60ff02c488933a318993881b3c
https://doi.org/10.1093/bjs/znab345

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

Autor: Charehbili, A., van de Ven, S., Smit, V.T.H.B.M., Meershoek-Klein Kranenbarg, E., Hamdy, N.A.T., Putter, H., Heijns, J.B., van Warmerdam, L.J.C., Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., van Laarhoven, H.W.M., Vriens, B., Wasser, M.N., van Leeuwen-Stok, A.E., Liefers, G.J., van de Velde, C.J.H., Nortier, J.W.R., Kroep, J.R. ^*

Publikováno v: In Annals of Oncology May 2014 25(5):998-1004

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.